文献速递眼底病与葡萄膜炎

L-精氨酸肽偶联纳米载体维持玻璃体内驻留

Sustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

研究合成以胆固醇葡聚糖为核心、偶联含L-精氨酸阳离子肽的纳米载体(直径小于50纳米),在离体玻璃体和啮齿类动物眼内评估扩散速率、半衰期及组织学毒性;发现扩散速率与zeta电位负相关,体内半衰期随zeta电位升高而延长至240天,组织学检查未见眼部形态与结构的不良影响。

要点

  • 纳米载体直径小于50纳米,偶联含1至4个精氨酸基团的阳离子肽。
  • 离体玻璃体中扩散速率与zeta电位呈负相关。
  • 体内半衰期随zeta电位升高而延长,最长至240天。

核心结论

  • 研究表明L-精氨酸肽偶联纳米载体有潜力成为后节眼病安全持续释放治疗药物的系统。

研究设计与样本

  • 合成以 condensed cholesteryl dextran(CDEX)为核心材料的纳米载体,表面偶联含1至4个精氨酸基团的阳离子肽及荧光标签。
  • 在离体玻璃体和啮齿类动物眼内用荧光成像监测载体扩散速率与体内半衰期。

主要发现

  • 纳米载体在新鲜分离玻璃体液中的扩散速率与zeta电位值呈负相关。
  • 体内半衰期随zeta电位升高而延长,最长至240天。
  • 组织学检查确认对眼部形态和组织结构无不良影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intravitreal injection of antiangiogenic agents is becoming a standard treatment for neovascular retinal diseases. Sustained release of therapeutics by injecting colloidal carriers is a promising approach to reduce the injection frequency, which reduces treatment burdens and the risk of complications on patients. Such sustained release often requires carriers to have micrometer-scale dimension that, however, can potentially promote glaucoma and inflammation. Small, polycationic particles can be immobilized in vitreous through multiple cooperative ionic interactions with hyaluronic acid of the vitreous interior, but such particles are generally toxic. Here, we synthesized and examined a biocompatible dextran-based nanocarrier (<50 nm in diameter) conjugated with cationic peptides containing L-arginine with minimal toxicity, aiming to provide sustained release of therapeutic drugs in vitreous. METHODS: We synthesized the nanocarriers with condensed cholesteryl dextran (CDEX) as core material. Cationic peptides containing 1 to 4 arginine groups, along with fluorescence tags, were conjugated to the CDEX surface. We monitored the carrier diffusion rate ex vivo and half-lives in vivo in rodent vitreous using fluorescence imaging. We evaluated the toxicity by histological examinations at the second, third, eighth, and thirty-sixth week. RESULTS: The diffusion rate of nanocarriers was inversely related to zeta potential values in freshly isolated vitreous humor. We observed increased half-lives in vivo with increasing zeta potential (up to 240 days). Histological examinations confirmed no adverse effects on ocular morphology and organization. CONCLUSIONS: We demonstrated the potential of L-arginine peptide-conjugated nanocarriers toward safe and sustained therapeutic release system for posterior eye diseases.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Li H, Liu W, Sorenson CM, et al. Sustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers. Invest Ophthalmol Vis Sci. 2017. PMID: 28986592. doi:10.1167/iovs.17-22160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。